Taken together, these results suggest that NLR, as a cost-effective and readily accessible inflammatory marker, outperforms CRP and UA, offering a more comprehensive and pathophysiologically relevant tool for risk stratification and inpatient gout recurrence surveillance in clinical practice. The gene discussed is CRP; the disease is gout.